Literature DB >> 32886190

Gut microbiota profile and selected plasma metabolites in type 1 diabetes without and with stratification by albuminuria.

Signe A Winther1,2, Peter Henriksen3, Josef K Vogt4, Tue H Hansen4, Linda Ahonen3,5, Tommi Suvitaival3, Emilie Hein Zobel3, Marie Frimodt-Møller3, Tine W Hansen3, Torben Hansen4, Hans-Henrik Parving6, Cristina Legido-Quigley3,7, Peter Rossing3,8, Oluf Pedersen9.   

Abstract

AIMS/HYPOTHESIS: Abnormal gut microbiota and blood metabolome profiles have been reported both in children and adults with uncomplicated type 1 diabetes as well as in adults with type 1 diabetes and advanced stages of diabetic nephropathy. In this study we aimed to investigate the gut microbiota and a panel of targeted plasma metabolites in individuals with type 1 diabetes of long duration without and with different levels of albuminuria.
METHODS: In a cross-sectional study we included 161 individuals with type 1 diabetes and 50 healthy control individuals. Individuals with type 1 diabetes were categorised into three groups according to historically measured albuminuria: (1) normoalbuminuria (<3.39 mg/mmol); (2) microalbuminuria (3.39-33.79 mg/mmol); and (3) macroalbuminuria (≥33.90 mg/mmol). From faecal samples, the gut microbiota composition at genus level was characterised by 16S rRNA gene amplicon sequencing and in plasma a targeted profile of 31 metabolites was analysed with ultra HPLC coupled to MS/MS.
RESULTS: Study participants were aged 60 ± 11 years (mean ± SD) and 42% were women. The individuals with type 1 diabetes had had diabetes for a mean of 42 ± 15 years and had an eGFR of 75 ± 25 ml min-1 (1.73 m)-2. Measures of the gut microbial beta diversity differed significantly between healthy controls and individuals with type 1 diabetes, either with micro- or macroalbuminuria. Taxonomic analyses showed that 79 of 324 genera differed in relative abundance between individuals with type 1 diabetes and healthy controls and ten genera differed significantly among the three albuminuria groups with type 1 diabetes. For the measured plasma metabolites, 11 of 31 metabolites differed significantly between individuals with type 1 diabetes and healthy controls. When individuals with type 1 diabetes were stratified by the level of albuminuria, individuals with macroalbuminuria had higher plasma concentrations of indoxyl sulphate and L-citrulline than those with normo- or microalbuminuria and higher plasma levels of homocitrulline and L-kynurenine compared with individuals with normoalbuminuria. Whereas plasma concentrations of tryptophan were lower in individuals with macroalbuminuria compared with those with normoalbuminuria. CONCLUSIONS/
INTERPRETATION: We demonstrate that individuals with type 1 diabetes of long duration are characterised by aberrant profiles of gut microbiota and plasma metabolites. Moreover, individuals with type 1 diabetes with initial stages of diabetic nephropathy show different gut microbiota and plasma metabolite profiles depending on the level of albuminuria. Graphical abstract.

Entities:  

Keywords:  16S RNA sequencing; Diabetes; Diabetic kidney disease; Diabetic nephropathy; Gut microbiota; Metabolome; Plasma metabolome; Renal complications; Targeted metabolites; Type 1 diabetes

Year:  2020        PMID: 32886190     DOI: 10.1007/s00125-020-05260-y

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  10 in total

Review 1.  The Kynurenine Pathway in Acute Kidney Injury and Chronic Kidney Disease.

Authors:  Hai Ning Wee; Jian-Jun Liu; Jianhong Ching; Jean-Paul Kovalik; Su Chi Lim
Journal:  Am J Nephrol       Date:  2021-11-09       Impact factor: 3.754

2.  Effects of Butyrate Supplementation on Inflammation and Kidney Parameters in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Ninna H Tougaard; Marie Frimodt-Møller; Hanne Salmenkari; Elisabeth B Stougaard; Andressa D Zawadzki; Ismo M Mattila; Tine W Hansen; Cristina Legido-Quigley; Sohvi Hörkkö; Carol Forsblom; Per-Henrik Groop; Markku Lehto; Peter Rossing
Journal:  J Clin Med       Date:  2022-06-21       Impact factor: 4.964

3.  Characteristics of Serum Metabolites and Gut Microbiota in Diabetic Kidney Disease.

Authors:  Bo Zhang; Yuzhou Wan; Xuefeng Zhou; Haojun Zhang; Hailing Zhao; Liang Ma; Xi Dong; Meihua Yan; Tingting Zhao; Ping Li
Journal:  Front Pharmacol       Date:  2022-04-14       Impact factor: 5.988

4.  Xylo-Oligosaccharides in Prevention of Hepatic Steatosis and Adipose Tissue Inflammation: Associating Taxonomic and Metabolomic Patterns in Fecal Microbiomes with Biclustering.

Authors:  Jukka Hintikka; Sanna Lensu; Elina Mäkinen; Sira Karvinen; Marjaana Honkanen; Jere Lindén; Tim Garrels; Satu Pekkala; Leo Lahti
Journal:  Int J Environ Res Public Health       Date:  2021-04-12       Impact factor: 3.390

Review 5.  Metabolomics in Diabetes and Diabetic Complications: Insights from Epidemiological Studies.

Authors:  Qiao Jin; Ronald Ching Wan Ma
Journal:  Cells       Date:  2021-10-21       Impact factor: 6.600

Review 6.  The Impact of Intestinal Microorganisms and Their Metabolites on Type 1 Diabetes Mellitus.

Authors:  Shu-Juan Zheng; Yi Luo; Jian-Hui Xiao
Journal:  Diabetes Metab Syndr Obes       Date:  2022-04-11       Impact factor: 3.249

Review 7.  The role and mechanisms of gut microbiota in diabetic nephropathy, diabetic retinopathy and cardiovascular diseases.

Authors:  Qiulan Lv; Zhiyuan Li; Aihua Sui; Xiaomin Yang; Yafei Han; Ruyong Yao
Journal:  Front Microbiol       Date:  2022-08-18       Impact factor: 6.064

8.  The Specific Alteration of Gut Microbiota in Diabetic Kidney Diseases-A Systematic Review and Meta-Analysis.

Authors:  Yuwei Wang; Jin Zhao; Yunlong Qin; Zixian Yu; Yumeng Zhang; Xiaoxuan Ning; Shiren Sun
Journal:  Front Immunol       Date:  2022-06-17       Impact factor: 8.786

9.  Gut microbiome and metabolic activity in type 1 diabetes: An analysis based on the presence of GADA.

Authors:  Sihui Luo; Tong Yue; Ziyu Liu; Daizhi Yang; Mengyun Xu; Yu Ding; Weiwei Jiang; Wen Xu; Jinhua Yan; Jianping Weng; Xueying Zheng
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-30       Impact factor: 6.055

10.  Faecal biomarkers in type 1 diabetes with and without diabetic nephropathy.

Authors:  Signe Abitz Winther; Miia Maininki Mannerla; Marie Frimodt-Møller; Frederik Persson; Tine Willum Hansen; Markku Lehto; Sohvi Hörkkö; Michael Blaut; Carol Forsblom; Per-Henrik Groop; Peter Rossing
Journal:  Sci Rep       Date:  2021-07-26       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.